Licensing deals

Hiker having trouble climbing mountain

Biotech

Processa hands cancer drug back to Opus over time, cost involved

The portfolio streamlining is meant to help Processa focus on another oncology asset, a modified precursor of approved chemotherapy 5-fluorouracil.

Darren Incorvaia Jul 1, 2025 11:12am

graphic art of a right hand signing something

Sanofi takes up option on Adagene biospecific, invests $25M

Jul 1, 2025 8:10am

business targets illustration

Argenx's $1.5B pact to turn macrocyclic peptides to new targets

Jul 1, 2025 8:00am

Two businessmen pushing giant puzzle pieces together as the sun sets behind them

Henlius pens $202M pact for HanchorBio's midstage CD47 blocker

Jul 1, 2025 3:50am

Collection of bright seamless colorful minimalistic patterns

Alphabet's Calico weaves anti-aging deal with China's Mabwell

Jun 26, 2025 4:52pm

A one dollar bill sitting next to a declining stock graph

Fierce Pharma

Vor Bio's surprise $4B revival deal splits investor reactions

Jun 26, 2025 10:55am